The prevalence of clinical signs and neuropathological findings of Alzheimer's disease (AD) is high in Down's syndrome (DS). In the general population, the apolipoprotein E (ApoE) €4 isoform is an important risk marker for AD. We studied the allelic frequencies of ApoE in 26 DS cases fulfilling clinical diagnostic criteria for AD and in 26 DS controls matched for age, sex, and premorbid level of mental retardation. A meta-analysis of data available in the literature was used for comparison with allele frequencies in other AD and control populations. ApoE type 2, 3, or 4 allele frequencies were not significantly different in AD-DS cases and DS controls. The ApoE €4 frequency in DS cases with AD (0.14; CI, 0.06-0.26) was significantly lower than in any other AD population studied so far and it is within the range of nondemented controls from the general population. These findings suggest that ApoE €4 does not significantly affect the pathogenesis of AD in DS patients. 
Prevalence estimates of dementia in populations with
Down's syndrome (DS) amount to 8, 5 5 , and 759% in the fifth, sixth, and seventh decades, respectively [ 1) . In virtually all cases of DS over 40 years of age senile plaques and neurofibrillary tangles characteristic of Alzheimer's disease (AD) are present within one or more regions of the brain [2] . Increased expression of the P-amyloid precursor gene located on chromosome 21 is thought to underly the development of these abnormalities in trisomy 21 12) .
In the general population, the apolipoprotein E (ApoE) €4 isoform is an important risk marker for developing AD, and in familial forms of A D €4 ApoE confers an earlier onset of dementia [3] . These observations fostered the hypothesis that ApoE rather than P-amyloid plays a central role in the pathogenesis of 
Materials and Methods
Subjects were ascertained through eight institutions for persons with mental retardation (specified in the footnotes). Mannheim, Germany) and visualized by ethidium bromide staining (Reymer PWA, Groenemeyer BE, van de Burg R, Kastelein JJP, unpublished data). Prior power calculations showed that a minimum of 50 alleles should be studied in each group to detect at least a twofold excess of ApoE €4 in AD-DS compared with DS controls, with an a-and p-error of 0.05 and 0.10, respectively.
For the meta-analysis of ApoE allele frequencies in controls and AD patients from the general population, a computer search in Medline for the period August 1093 to October 1994 was performed using "apolipoprotein E ' and "Alzheimer's disease" as search terms. Retrieved articles or letters to the editor, excluding abstracts, in which original research was described were identified. We only included studies if (1) well-described diagnostic criteria for A D were used, (2) data presentation was in such a manner that €4 ApoE allele frequencies could be calculated, and (3) the A D group contained at least 25 patients.
Allele frequencies were estimated by counting alleles and calculating sample proportions. Comparisons of genotype frequencies and allele frequencies were made using the x2 statistic or Fisher's exact test. as appropriate. Differences in age of onset and duration of symptoms according to the presence of the €4 allele in AD-DS cases were analyzed statistically by the unpaired r test.
Results
A total of 52 subjects with DS were included in the study. There were no significant differences between the AD-DS cases and DS controls in age, sex, and premorbid level of functioning ( Table 1 ). The frequency of the most common genotype (ApoE 3 / 3 ) was similar in both groups. The ApoE type 2, 3 , and 4 allele frequencies were not significantly different in AD-DS cases and DS-control subjects (see Table 1 The results of the meta-analysis of studies performed in non-DS populations showed increased ApoE €4 allele frequencies in all cohorts with AD, which were most prominent in those with familial onset and with lateonset of A D (Table 2 and Fig) . The ApoE €4 frequency found in the AD-DS cases is significantly lower than in any other A D population studied so far, and it is within the range of published general population data on nondemented subjects (see Table 2 and Fig) [12] .
Discussion
Since the pivotal observations of the Duke University group on the association between the ApoE €4 allele and A D [6, 19, 20, 22, 231 , numerous studies have replicated this finding in various populations of AD patients with different hereditary components, ages of onset, and ethnic backgrounds (see Fig for references) . The €4 ApoE allele frequency in the AD-DS cases described here is particularly interesting because it is the first clinically diagnosed A D population of reasonable size in which such low figures were found. In our population of AD-DS cases of ApoE €4 frequency was only slightly higher than in nondernented DS controls and it was similar to that in nondemented controls from the general population C 12). Several explanations may account for this unexpected observation. First, difficulties in diagnosing A D in the general population are well established and diagnosing this condition in individuals with mental retardation is even more difficult than in persons with normal intelligence and psychosocial functioning C4 1). Applying diagnostic criteria designed for populations without mental retardation may elicit numerous false-positive classifications if used in a DS population. This may lead to underestimation of real differences in €4 allele frequencies between AD-DS and DS controls. However, to minimize the risk of bias we studied institutionalized patients, which enabled us to use criteria relying heavily on long-standing, careful observations in daily life, using comparison with former actual levels of psychosocial functioning, rather than applying a single clinical and neuropsychological assessment. Also careful exclusion of various conditions other than A D that can impair the level of functioning in persons with DS should have minimized diagnostic misclassifications.
Second, excess mortality in AD-DS cases carrying €4 alleles may have obscured hypothetical true differences between cases and controls. However, we found no effects of the €4 allele presence on disease duration, rendering this explanation unlikely. Moreover, the €4 allele frequencies in AD-DS cases and in DS controls reported here are within the range of those found in .4
Mayew ( 3 I I Kuusiw) [32] Yoshizdwa A population with such a high risk for developing AD, as the DS population studied here, is extremely suitable to study putative protective factors for not developing AD. Several studies suggest that €2 ApoE may reduce the risk of developing AD 123, 24, 26, 401 . This observation led to the hypothesis that ApoE genotypes may modulate the risk for AD by differentially affecting the rate of phosphorylation of 7 to form neurofibrillary tangles [3] . According to this hypothesis €4 ApoE would stimulate tangle formation, whereas €2 would protect against neurofibrillary degeneration. However, we found no excess €2 alleles in our DS controls, not even among the 14 elderly nondemented DS individuals over 55 years of age (0.15 €2 alleles; confidence interval [CI], 0.04-0.35). Our study was initially designed to study differences in €4 allele frequencies, and given the low prevalence of €2 alleles, the power of our study may have been too limited to draw any conclusion concerning the absence of a protective allele €2 effect in this specific population.
Apart from these considerations relating to the pathogenesis of AD, the present results may also have practical implications. When the first reports on the excess of €4 alleles in A D appeared, several authors suggested that ApoE genotyping could be a tool for identifying individuals with increased risk for developing AD C28, 30, 35, 44 , 451 although preliminary analyses already predicted that the practical usefulness of ApoE genotyping for such a purpose will be poor in the general population 146, 471. Based on our present results it can be concluded that ApoE genotyping for diagnostic purposes will certainly not be feasible in DS populations. In a similar manner, it has been speculated that manipulation of the ApoE-driven pathogenetic pathways may offer new therapeutic opportunities I 1 7, 40, 44, 481 , whereas the present results strongly suggest that it is not useful to pursue such efforts in AD-DS patients.
In conclusion, whatever the relative contribution of either ApoE or P-amyloid in the pathogenesis of AD may be in the general population, the absence of excess of €4 alleles in AD-DS patients as documented in our study suggests that the role ApoE €4 plays in causing AD in individuals with DS is of minor importance. This conclusion may have implications for future studies into diagnostic and therapeutic efforts in AD-DS and it reinforces the idea that AD is an etiologically heterogeneous disorder.
